anti-mucin-1/CD16A bispecific antibody BGB-B3227

An immunoglobulin G1 (IgG1) humanized bispecific antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1) and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-MUC1/CD16A bispecific antibody BGB-B3227 targets and binds to CD16A expressed on natural killer (NK) cells and MUC1 expressed on the surface of tumor cells, thereby selectively cross-linking tumor and NK cells. This may result in NK cell activation and eventually tumor cell lysis. CD16A is specifically expressed on the surface of NK cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.